The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma

Aberrant receptor kinase signalling and tumour neovascularization are hallmarks of medulloblastoma development and are both considered valuable therapeutic targets. In addition to VEGFR1/2, expression of PDGFR α/β in particular has been documented as characteristic of metastatic disease correlating...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehrhardt, Michael, Craveiro, Rogerio B., Velz, Julia, Olschewski, Martin, Casati, Anna, Schönberger, Stefan, Pietsch, Torsten, Dilloo, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867109/
https://www.ncbi.nlm.nih.gov/pubmed/29377550
http://dx.doi.org/10.1111/jcmm.13489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867109/
https://www.ncbi.nlm.nih.gov/pubmed/29377550
http://dx.doi.org/10.1111/jcmm.13489

Ejemplares similares